
Your Feed
Etentamig: A New BCMA Bispecific Antibody Showing Safety & Promise | Muhamed Baljevic, MD | #EHA2025
Etentamig: A New BCMA Bispecific Antibody Showing Safety & Promise | Muhamed Baljevic, MD | #EHA2025
The Importance of Joining Clinical Trials | Sunil Gupta, FCRPath, MRCP, DNB | EHA 2025 #myeloma
The Importance of Joining Clinical Trials | Sunil Gupta, FCRPath, MRCP, DNB
The Importance of Joining Clinical Trials | Sunil Gupta, FCRPath, MRCP, DNB
The Importance of Joining Clinical Trials | Sunil Gupta, FCRPath, MRCP, DNB | EHA 2025 #myeloma
Diagnosing Myeloma? Don’t Skip This Critical Amyloidosis Test! Jahanzaib Khwaja, MD, FRCPath
Diagnosing Myeloma? Don’t Skip This Critical Amyloidosis Test! Jahanzaib Khwaja, MD, FRCPath
What is immune effector cell associated hematotoxicity (ICHAT)? Which myeloma therapies are associated with ICHAT? How is ICHAT managed?
New Hope for MRD Recurrence? Daratumumab Proof-of-Concept Study | Krzysztof Jamroziak, MD | #EHA2025
New Hope for MRD Recurrence? Daratumumab Proof-of-Concept Study | Krzysztof Jamroziak, MD | #EHA2025




